Singular Health’s (ASX:SHG) investment in additive manufacturing company Additive Engineering is starting to pay off with AE’s facility now commercially operational.

The company first acquired a 25% stake in AE back in March 2021 through a $300,000 investment.

Since then, AE has progressed with the lease and fit out of a commercial facility in southwest Melbourne that includes the lease and installation of three metal 3D printers capable of printing biocompatible titanium and stainless steel and two polymer 3D printers.

This has already delivered first revenues through the production of a titanium cutting and drilling guide for a maxillofacial patient.

Additionally, AE has reached a production sharing agreement with Device Technologies.

This grants Device Technologies, a leading medical technology supplier with over 1000 staff in Australia, with preferred access to AE’s facility in exchange for re-selling its services.

Singular Health can also access and use AE’s printing services for all bio-models, guides, and implants directly through its 3Dicom and VSP software.

“Access to advanced manufacturing capabilities, including 3D printing, is an essential part of Singular Health’s Scan to Surgery process and is the last step prior to the surgery itself,” Singular chief executive Thomas Hanly said.

“The workflows used by Additive Engineering demonstrates the commercial and clinical viability of the patient-specific implant design and print process.

“We are very excited to see our investment come to fruition in just 11 months with the commissioning and first print now completed.”




This article was developed in collaboration with Singular Health, a Stockhead advertiser at the time of publishing.


This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.